



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1996PLC086681

Date: May 30, 2026

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001

Sub: Outcome of board meeting held today i.e. 30th May, 2026.

Ref.: Norris Medicines Limited, Scrip Code- 524414

Dear Sir/Madam,

Pursuant to Regulation 30 & 33 of Chapter IV read with schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and in continuation to our letter dated May 25, 2026, about intimating the date of Board Meeting of Norris Medicines Limited ("**Company**"), we would like to inform you that the Board of Directors at their Meeting held today i.e. Saturday, May 30, 2026 inter-alia considered, noted and approved the following:

1. Considered and approved Audited Financial Results along with Audit Report for the quarter and year ended March 31, 2026.
A copy of the Audited Financial Results along with the **Audit Report, Statement of asset and liability, Cashflow Statement and Declaration of unmodified opinion** by the auditor thereon, issued in this regard is enclosed herewith as "**Annexure A**".
We are arranging to publish the said Financial Results in newspapers in the format prescribed under Regulation 47 of Listing Regulations.
2. Approved the appointment of **M/s. Dhiren Y Parikh & Co., Chartered Accountants**, as Internal Auditors for the FY 2026-2027 at the Board Meeting of the Company;
Disclosure of Information pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 is enclosed as "**Annexure B**".
3. Declaration with respect to Un-modified opinion on the Audited Financial Results pursuant to Regulation 33(3)(d) of the SEBI (LODR) Regulation, 2015 is enclosed herewith.

The meeting of Board of Directors commenced at 03:00 p.m. and concluded at 03:30 p.m.
You are requested to take the aforementioned information on your record.

Thanking you.
Yours Faithfully

For NORRIS MEDICINES LIMITED

VIMAL D. SHAH
DIRECTOR
DIN: 01506655
Encl.: As above.

BAHEDIA & ASSOCIATES

Chartered Accountants

SF-68 & 69, Hexzone Arcade, Beside Jayaben Modi Hospital, Valia Road,
GIDC, ANKLESHWAR - 393 002. Office : (M) : 84011 20412

CA. B. L. Bahedia
(FCA., LL.B., D.T.P., B.Com.)



Mobile No. : +91 98241 36264, 97252 20412
E-mail : bbahedia@yahoo.com/gmail.com

Independent Auditor's Report on the quarterly and year to date Audited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Director's,
Norris Medicines Limited
Report on the Audit of the Standalone Financial Statements**

Opinion


We have audited the accompanying standalone quarterly financial statements and year-to-date standalone financial results of **Norris Medicines Limited** ("the Company") for the quarter and the year ended March 31, 2026 as well as the year-to-date results for the period from April 1, 2025 to March 31, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us, these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the net profit/loss and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2026 as well as the year-to-date results for the period from April 1, 2025 to March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013 (the Act), as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company



in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter Paragraph

Our opinion is not modified in respect of this matter.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year-to-date standalone financial results have been prepared on the basis of the interim financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of these financial results that give a true and fair view of the net loss and other comprehensive income of the Company and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.



Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



BAHEDIA & ASSOCIATES

Chartered Accountants

SF-68 & 69, Hexzone Arcade, Beside Jayaben Modi Hospital, Valia Road,
GIDC, ANKLESHWAR - 393 002. Office : (M) : 84011 20412

CA. B. L. Bahedia
(FCA., LL.B., D.T.P., B.Com.)



Mobile No. : +91 98241 36264, 97252 20412
E-mail : bbahedia@yahoo.com/gmail.com

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


For, BAHEDIA & ASSOCIATES
CHARTERED ACCOUNTANTS
(FRN: 114421W)

(CA. B.L. BAHEDIA)
PROPRIETOR
M. No. 048066

UDIN: 26048066QAMB L R8572

Place: ANKLESHWAR
Date: 30/05/2026





NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P & 901/3,4,5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com

CIN No., L24230GJ1990PLC086581

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.03.2026						
Rs. In Lakhs						
Sl. No.	Particulars	QUARTER ENDED			YEAR ENDED	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
		Audited - Refer Note 5	Unaudited	Audited - Refer Note 5	Audited - Refer Note 5	Audited
1	(a) Revenue from Operations	140.84	326.66	272.09	813.20	582.02
	(b) Other Income	2.07	0.01	4.53	4.54	6.13
	Total Income From Operations (Net)	142.91	326.67	276.62	817.74	588.15
2	Expenses					
	a. Cost of Materials Consumed	74.66	7.32	145.46	434.06	337.10
	b. Changes in Inventories of Finished Goods, work in Progress and stock in trade	-30.72	134.72	30.98	-3.60	8.06
	c. Employee Benefit Expenses	33.21	48.22	51.45	166.90	140.72
	d. Finance Costs	15.44	12.59	14.55	50.00	43.96
	e. Depreciation and Amortisation Expense	12.33	12.25	13.94	49.08	53.70
	f. Other expenditure	32.93	41.83	37.15	149.36	122.42
	Total Expenses	137.85	256.93	293.53	845.80	705.96
3	Profit/ Loss before Tax (1-2)	5.06	69.74	-16.91	-28.06	-117.81
4	Tax Expense					
	a: Current Tax	0.00	0.00	0.00	0.00	0.00
	b: Deferred Tax	0.00	0.00	5.94	0.00	5.94
5	Profit / Loss after Tax	5.06	69.74	-22.85	-28.06	-123.75
6	Other Comprehensive Income					
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00
7	Total Comprehensive Income for the period	5.06	69.74	-22.85	-28.06	-123.75
8	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58
9	- Basic and diluted	0.05	0.70	-0.23	-0.28	-1.24



For NORRIS MEDICINES LTD.

(Signature)
Authorised Signatory



NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P & 901/3,4,5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

STATEMENT OF ASSETS AND LIABILITIES OF NORRIS MEDICINES LIMITED		As At 31.03.2026 (Audited)	As At 31.03.2025 (Audited)
A . ASSETS			
1. Non Current Assets			
a) Property, Plant & Equipment		478.66	526.77
b) Capital Work in Progress			
c) Investment Property			
d) Financial Assets			
i) Investments		0.95	0.95
ii) Loans		10.61	1.99
iii) Others		41.71	41.80
e) Non Current Tax Assets (Net)		90.40	90.40
f) Other Non Current Assets		85.33	84.76
TOTAL NON CURRENT ASSETS		707.66	746.67
2. Current Assets			
a) Inventories		398.43	412.81
b) Financial Assets			
i) Trade Receivables		117.40	140.90
ii) Cash and Cash Equivalents		2.16	3.98
iii) Bank Balance other than "b" above.			
iv) Loans			
v) Others		63.28	76.62
TOTAL CURRENT ASSETS		581.27	634.31
TOTAL ASSETS		1288.94	1380.98
B. EQUITY & LIABILITIES			
1) Equity			
a) Equity Share Capital		992.58	992.58
b) Other Equity		-2507.39	-2479.33
Total Equity		-1514.80	-1486.75
2) Non Current Liabilities			
a) Financial Liabilities - Borrowings		1851.22	1852.74
b) Provisions			
c) Deferred Tax Liabilities (Net)			
d) Non Current Tax Liabilities (Net)			
Total Non - Current Liabilities		1851.22	1852.74
3) Current Liabilities			
a) Financial Liabilities			
i) Borrowings		302.31	305.31
ii) Trade payables		262.19	302.55
iii) Other financial liabilities		116.29	133.18
b) Other Current Liabilities		0.00	0.00



NORRIS MEDICINES LTD.

Authorized Signatory



NORRIS MEDICINES LIMITED



Factory : Plot No. 801/P & 901/3,4,5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002 (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

c) Provisions	271.76	273.96
Total Current Liabilities	952.54	1015.00
TOTAL EQUITY AND LIABILITIES	1288.94	1380.98

Notes:

- 1) The above results were reviewed by the Audit Committee and have been taken on record by the Board of Directors of the Company in their respective meeting held on 30.05.2026. The above results have been subjected to Audit by the Statutory Auditors of the Company. The report of Statutory Auditors is unqualified.
- 2) The Standalone Financial Results for the year ended March 31, 2026 were audited by the Statutory Auditors of the Company and have expressed an unmodified opinion on the results.
- 3) The entire Operations of the Company relate to only one segment hence reporting as defined in AS17 is not applicable.
- 4) The figures for the quarter ended March 31, 2026, are balancing figures between the Audited figures in respect of the full financial year and published year to date figures upto the third quarter of the current financial year.
- 5) There are no related party transaction during the Half year ending 31st March, 2026. Accordingly, the disclosures for Non-applicability of Related Party Transaction is provided in Integrated Financials Filing
- 6) Previous year figures have been regrouped or reclassified wherever necessary
- 7) There are no outstanding defaults on loans and debt securities, therefore statement on the same is not forming part of these results.
- 8) The Quarterly and Yearly Financial Results of the Company have been prepared in accordance with The Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.



For Norris Medicines Limited
For NORRIS MEDICINES LTD.

Vimal D Shah
 Managing Director

Date: 30.05.2026
 Place: Ankleshwar





NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P & 901/3,4,5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

NORRIS MEDICINES LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH 2026

		2025-2026	2024-2025
		Rs.Ps	Rs.Ps
(A)	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit/Loss before tax and extraordinary items	-28.06	-123.75
	Adjustments for :		
	Depreciation & Amortisation	49.08	53.70
	Deferred Tax Liability	0	5.94
	Interest Income	-2.00	-1.85
	Interest Paid	50.00	43.96
	Profit/Loss on Investment in bonds	-	-
	Profit/Loss on sale of Fixed Assets	-	-
	Other Non Operating Income	-	-
	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	69.02	-22.00
	Adjustments for Changes in Working Capital		
	Increase/Decrease in Trade Debtors	23.50	-34.84
	Increase/Decrease in Inventories	14.38	20.54
	Increase/Decrease in Loans & Advances	13.32	-5.14
	Trade Payables and Other Liabilities	-62.46	92.44
	Net cash from operations before taxation	-11.26	73.00
	Tax Paid	-	-
	CASH FLOW BEFORE EXTRA ORDINARY ITEM	-11.26	51.00
	Extra Ordinary Item	-	-
	NET CASH FROM OPERATING ACTIVITIES	57.76	51.00
(B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets	-0.96	-1.90
	Sale of Fixed Assets		0
	Investments Made during the year	0	0
	Long Term Advances	-9.10	0.00
	Receipt from Investment	0	-0.33
	Interest Income	2.00	1.85
	Dividend Received	0	0
	Profit/Loss on sale of bonds	0	0
	Net Cash used in Investing Activities (B)	-8.06	-0.38
(C)	CASH FLOW FROM FINANCING ACTIVITIES:-		
	Share Capital	-	-
	Borrowings	-1.52	-6.43
	Interest paid	-50.00	-43.96
	Net Cash Used in Financing Activities (C)	-51.52	-50.39



For NORRIS MEDICINES





NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P & 901/3,4,5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Net Increase/Decrease in Cash and Cash Equivalents (A+B+C)	-1.82	0.23
Cash and Cash equivalents - Opening balance	3.98	3.75
Cash and cash equivalents - Closing balance	2.16	3.98
	1.82	-0.23
Component of Cash & Cash Equivalents:		
Cash on hand	0.96	1.29
With Banks in Current Accounts	1.20	2.69
	2.16	3.98

Date: 30.05.2026
Place: Ankleshwar

For Norris Medicines Limited
For NORRIS MEDICINES LTD.
Vimal D Shah
Managing Director
Authorized Signatory





NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1996PLC886581

Date: May 30, 2026

To,
BSE Limited,
Department of Corporate Service (DCS-CRD),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001.

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2015, in respect of Independent Auditors Report with Unmodified Opinion.

Ref.: Norris Medicines Limited, Scrip Code-524414

Declaration

I Vimal Dharendra Shah, Managing Director (DIN: 01506655) of the Company hereby declare that M/s. Bahedia and Associates, Chartered Accountant (Firm Registration Number 114421W), Statutory Auditor of the Company, have issued the Independent Audit Report with unmodified opinion in respect of the Audited Financial Results of the Company for the quarter and year ended 31st March, 2026.

This declaration is given in compliance to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CMD/56/2016 dated May 27, 2016

Kindly take the same on your records.

For NORRIS MEDICINES LIMITED

VIMAL D. SHAH
DIRECTOR
DIN: 01506655



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1996PLC086581

Annexure B

Disclosure of Information pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Name of the Auditor	M/s. Dhiren Y Parikh & Co., Chartered Accountants
Reason for change viz. appointment, resignation, removal, death or otherwise.	Appointment as Internal Auditor of the Company
Date of appointment/cessation (as applicable) and term of appointment	<u>Date of Appointment:</u> 30 th May, 2026 <u>Term of appointment:</u> M/s. Dhiren Y Parikh & Co., Chartered Accountants is appointed as Internal Auditors of the Company for the FY 2026 - 2027.
Brief Profile	M/s. Dhiren Y Parikh & Co., Chartered Accountants operates as a private, operating firm. The firm primarily provides audit, consulting, taxation, accounting, and corporate advisory services. They have a strong background in designing and implementing internal control systems and ensuring regulatory compliance. The Board is confident that their appointment will strengthen the Company's internal audit framework and contribute to enhanced transparency and accountability.
Disclosure of Relationship with other Directors and Key Managerial Personnel of the Company	Not Applicable

For NORRIS MEDICINES LIMITED

VIMAL D. SHAH
DIRECTOR
DIN: 01506655